Top Insights
J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target.
The post Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy appeared first on MedCity News.
Leave a comment